Amalgamated Bank’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $8.13M | Buy |
48,241
+673
| +1% | +$99.8K | 0.06% | 271 |
|
|
2026
Q1 | $6.27M | Buy |
47,568
+794
| +2% | +$105K | 0.05% | 319 |
|
|
2025
Q4 | $6.63M | Sell |
46,774
-1,135
| -2% | -$164K | 0.05% | 311 |
|
|
2025
Q3 | $6.72M | Buy |
47,909
+649
| +1% | +$87.9K | 0.05% | 303 |
|
|
2025
Q2 | $5.94M | Sell |
47,260
-459
| -1% | -$52.6K | 0.05% | 323 |
|
|
2025
Q1 | $5.28M | Sell |
47,719
-1,895
| -4% | -$240K | 0.05% | 348 |
|
|
2024
Q4 | $6.77M | Sell |
49,614
-916
| -2% | -$113K | 0.06% | 278 |
|
|
2024
Q3 | $5.82M | Sell |
50,530
-1,541
| -3% | -$211K | 0.05% | 339 |
|
|
2024
Q2 | $7.17M | Sell |
52,071
-3,098
| -6% | -$425K | 0.06% | 271 |
|
|
2024
Q1 | $7.61M | Sell |
55,169
-12,814
| -19% | -$1.75M | 0.07% | 276 |
|
|
2023
Q4 | $8.96M | Sell |
67,983
-703
| -1% | -$80.9K | 0.07% | 252 |
|
|
2023
Q3 | $7.73M | Sell |
68,686
-1,269
| -2% | -$134K | 0.07% | 273 |
|
|
2023
Q2 | $6.6M | Sell |
69,955
-1,959
| -3% | -$191K | 0.05% | 322 |
|
|
2023
Q1 | $7.28M | Sell |
71,914
-2,120
| -3% | -$221K | 0.06% | 286 |
|
|
2022
Q4 | $8.84M | Buy |
74,034
+323
| +0.4% | +$37.8K | 0.08% | 226 |
|
|
2022
Q3 | $7.83M | Buy |
73,711
+2,089
| +3% | +$212K | 0.08% | 228 |
|
|
2022
Q2 | $6.98M | Buy |
71,622
+960
| +1% | +$88.6K | 0.07% | 275 |
|
|
2022
Q1 | $6.63M | Buy |
70,662
+14
| +0% | +$1.19K | 0.05% | 337 |
|
|
2021
Q4 | $6.02M | Buy |
70,648
+3,389
| +5% | +$312K | 0.04% | 419 |
|
|
2021
Q3 | $6.45M | Sell |
67,259
-7,044
| -9% | -$665K | 0.05% | 363 |
|
|
2021
Q2 | $7.23M | Buy |
74,303
+56,987
| +329% | +$5.46M | 0.06% | 337 |
|
|
2021
Q1 | $1.68M | Sell |
17,316
-1,290
| -7% | -$135K | 0.06% | 305 |
|
|
2020
Q4 | $1.78M | Buy |
18,606
+4
| +0% | +$386 | 0.07% | 272 |
|
|
2020
Q3 | $1.79M | Sell |
18,602
-478
| -3% | -$55.3K | 0.08% | 226 |
|
|
2020
Q2 | $2.33M | Sell |
19,080
-4,798
| -20% | -$530K | 0.11% | 147 |
|
|
2020
Q1 | $2.07M | Sell |
23,878
-375
| -2% | -$36.7K | 0.05% | 341 |
|
|
2019
Q4 | $2.61M | Buy |
24,253
+1,472
| +6% | +$154K | 0.05% | 372 |
|
|
2019
Q3 | $2.05M | Buy |
22,781
+2,789
| +14% | +$261K | 0.04% | 429 |
|
|
2019
Q2 | $1.69M | Sell |
19,992
-412
| -2% | -$33.8K | 0.04% | 492 |
|
|
2019
Q1 | $1.8M | Buy |
20,404
+450
| +2% | +$37.6K | 0.04% | 444 |
|
|
2018
Q4 | $1.43M | Buy |
19,954
+7,742
| +63% | +$742K | 0.04% | 476 |
|
|
2018
Q3 | $1.5M | Sell |
12,212
-8,611
| -41% | -$977K | 0.04% | 484 |
|
|
2018
Q2 | $2.05M | Buy |
20,823
+1,911
| +10% | +$171K | 0.05% | 372 |
|
|
2018
Q1 | $1.57M | Buy |
18,912
+1,428
| +8% | +$121K | 0.04% | 483 |
|
|
2017
Q4 | $1.36M | Buy |
17,484
+947
| +6% | +$64.6K | 0.04% | 569 |
|
|
2017
Q3 | $1.01M | Buy |
16,537
+386
| +2% | +$20.4K | 0.03% | 648 |
|
|
2017
Q2 | $743K | Buy |
16,151
+3,602
| +29% | +$175K | 0.02% | 791 |
|
|
2017
Q1 | $543K | Sell |
12,549
-2,766
| -18% | -$119K | 0.03% | 791 |
|
|
2016
Q4 | $593K | Buy |
15,315
+1,585
| +12% | +$71.7K | 0.03% | 753 |
|
|
2016
Q3 | $695K | Buy |
13,730
+1
| +0% | +$50 | 0.04% | 562 |
|
|
2016
Q2 | $662K | Buy |
13,729
+4,735
| +53% | +$218K | 0.04% | 592 |
|
|
2016
Q1 | $356K | Buy |
8,994
+785
| +10% | +$31.1K | 0.03% | 764 |
|
|
2015
Q4 | $464K | Sell |
8,209
-745
| -8% | -$37.9K | 0.06% | 487 |
|
|
2015
Q3 | $356K | Buy |
8,954
+117
| +1% | +$5.66K | 0.04% | 760 |
|
|
2015
Q2 | $422K | Buy |
8,837
+375
| +4% | +$15.9K | 0.04% | 697 |
|
|
2015
Q1 | $336K | Buy |
+8,462
| New | +$303K | 0.04% | 626 |
|
Other funds holding NBIX
Amalgamated Bank's NBIX Position: Q2 2026 in Review
Amalgamated Bank increased its Neurocrine Biosciences (NBIX) stake by 1.4% in Q2 2026, buying an estimated $99.8K and bringing the position to 48,241 shares worth $8.13M. The position accounts for 0.06% of the portfolio, ranked #271.
Amalgamated Bank first reported a position in NBIX in Q1 2015 and has held it in 46 quarters since. The position peaked at $8.96M in Q4 2023. 388 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Amalgamated Bank held 48,241 shares of Neurocrine Biosciences worth $8.13M as of Q2 2026.
- Amalgamated Bank bought 673 Neurocrine Biosciences shares in Q2 2026, an estimated $99.8K.
- Neurocrine Biosciences made up 0.06% of Amalgamated Bank's portfolio in Q2 2026, its #271 holding.
- Amalgamated Bank first reported a position in Neurocrine Biosciences in Q1 2015 and has held it in 46 quarters since.
- Amalgamated Bank's Neurocrine Biosciences position peaked at $8.96M in Q4 2023.
- 388 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.